Mangalam Drugs And Organics Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2012 • Bulk Drugs: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company generates healthy free cash flow
CONS
- Receivables are growing faster than sales - a possible quality concern
- Promoter holding has decreased over last 2 years: -14.7pp
- Company has a low return on equity of -0.2% over last 3 years
- Company has a low return on capital employed of 5.4%
- Interest coverage is weak at 1.3x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1930.45 | 38.29 | 463179.62 | 0.83 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9165.00 | 83.18 | 243301.95 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4958.95 | 86.48 | 188622.52 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1164.05 | 25.73 | 116114.43 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1418.00 | 33.99 | 114554.33 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1860.00 | 91.92 | 100498.07 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2150.00 | 17.78 | 98312.16 | 0.84 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1171.00 | 30.33 | 97741.02 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2360.00 | 47.72 | 97478.64 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1683.00 | 26.08 | 96836.10 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2464.20 | 38.68 | 69545.80 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MANGALAM | 29.99 | 0.00 | 47.47 | 0.00 | -7.64 | 44.64 | 57.12 | -0.16 | 8.55 | 1.58 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87 | 81 | 97 | 102 | 76 | 80 | 89 | 73 | 57 | 49 | 58 | 67 | 57 | |
| 91 | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 | 52 | 60 | 73 | 64 | |
| Operating Profit | -3 | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 | -3 | -1 | -5 | 1 |
| OPM % | -4.00% | 2.70% | 7.18% | 11.48% | 10.72% | 10.91% | 9.90% | 13.60% | -7.88% | -5.77% | -2.52% | -7.98% | 1.56% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 3 | 4 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 4 |
| -10 | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 | -12 | -10 | -13 | -7 | |
| Tax % | 7.29% | 25.05% | -1150.00% | 9.90% | -355.93% | -124.17% | 5.41% | 91.33% | -6.19% | 41.39% | -0.00% | -1.16% | -13.41% |
| Net Profit | -10 | -4 | 0 | 4 | 3 | 3 | 1 | 0 | -14 | -7 | -10 | -13 | -8 |
| -6 | -2 | 0 | 2 | 2 | 2 | 1 | 0 | -9 | -5 | -6 | -8 | -0 | |
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 295 | 303 | 279 | 228 | 282 | 385 | 451 | 372 | 369 | 318 | 232 | |
| 257 | 257 | 233 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 249 | |
| Operating Profit | 38 | 46 | 48 | 10 | 25 | 58 | 49 | 26 | 17 | 36 | — |
| OPM % | 13 | 15 | 17 | 4 | 9 | 15 | 11 | 7 | 5 | 11 | — |
| Other Income | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 16 |
| Depreciation | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -42 | |
| Tax % | 33 | 29 | 32 | -40 | -32 | 29 | 29 | 43 | 18 | -39 | 10 |
| Net Profit | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -38 |
| EPS | 0 | 0 | 0 | 0 | 0 | 18 | 12 | 1 | -6 | 4 | — |
| Dividend Payout % | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 11 | 14 | 13 | -5 | 5 | 18 | 12 | 1 | -6 | 4 | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 4%
- 5 Years:
- 2%
- 3 Years:
- -11%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 1%
- 5 Years:
- -3%
- 3 Years:
- -29%
STOCK PRICE CAGR
- 10 Years:
- -16%
- 5 Years:
- -27%
- 3 Years:
- -34%
- 1 Year:
- -60%
RETURN ON EQUITY
- 10 Years:
- 13%
- 5 Years:
- 7%
- 3 Years:
- 0%
- Last Year:
- 5%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - | - | - | - |
| Equity Capital | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| 39 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | |
| 43 | 41 | 51 | 51 | 42 | 57 | 54 | 56 | 75 | 72 | |
| Trade Payables | 21 | 21 | 38 | 32 | 57 | 43 | 55 | 95 | 83 | 91 |
| 43 | 42 | 35 | 33 | 28 | 33 | 70 | 55 | 57 | 47 | |
| Total Liabilities | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
| ASSETS | - | - | - | - | - | - | - | - | - | - |
| 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | |
| Capital Work in Progress | 5 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 |
| 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 47 | 37 | 60 | 73 | 65 | 59 | 117 | 137 | 124 | 139 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 39 | |
| Cash & Bank | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 1 | 3 |
| 53 | 57 | 64 | 33 | 62 | 82 | 74 | 77 | 57 | 23 | |
| Total Assets | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
| Total Debt | 60 | 66 | 69 | 63 | 50 | 64 | 79 | 75 | 95 | 88 |
| Net Working Capital | 27 | 18 | 23 | 14 | 10 | 25 | 55 | 40 | 19 | 14 |
| Contingent Liabilities | 6 | 7 | 2 | 7 | 7 | 31 | 46 | 26 | 12 | 35 |
| Book Value per Share | 36.89 | 54.15 | 65.56 | 60.44 | 65.67 | 82.63 | 95.12 | 96.00 | 89.93 | 93.92 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 12 | 43 | |
| Cash from Investing | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | -18 | -19 |
| Cash from Financing | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | 6 | -22 |
| -0 | 0 | -0 | 1 | 0 | -1 | 1 | -1 | -0 | 2 | |
| Free Cash Flow | 11 | 5 | 9 | 13 | 24 | -2 | 3 | 21 | -7 | 23 |
| OCF / Net Profit | 1.36 | 1.92 | 1.24 | -2.70 | 3.70 | 0.98 | 1.31 | 29.99 | -1.34 | 6.18 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 61 | 48 | 46 | 58 | 39 | 38 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 11.15 | 14.07 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 |
| Book Value (₹) | 36.89 | 54.15 | 65.56 | 60.44 | 65.67 | 82.63 | 95.12 | 96.00 | 89.93 | 93.92 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 14.22 | 17.24 | 16.72 | -0.60 | 10.41 | 23.47 | 18.89 | 7.74 | 3.53 | 14.72 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 12.44% | 14.79% | 15.50% | 3.86% | 7.94% | 15.08% | 10.89% | 7.03% | 4.71% | 11.25% |
| Net Margin % | 5.29% | 7.13% | 6.46% | -3.10% | 2.64% | 7.27% | 4.36% | 0.34% | -2.46% | 2.18% |
| ROE % | 38.91% | 32.11% | 20.99% | -8.05% | 8.27% | 23.83% | 13.97% | 0.84% | -6.15% | 4.76% |
| ROCE % | 29.14% | 30.18% | 25.35% | 1.76% | 10.66% | 28.01% | 18.34% | 6.65% | 1.23% | 8.40% |
| 9.73% | 12.76% | 9.56% | -3.67% | 3.73% | 11.31% | 6.64% | 0.37% | -2.53% | 1.93% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 45 | 39 | 49 | 44 | 34 | 45 | 41 | 46 | 37 | 38 |
| Inventory Days | 63 | 49 | 58 | 94 | 81 | 59 | 71 | 125 | 129 | 151 |
| Payable Days | 68 | 39 | 64 | 83 | 83 | 72 | 58 | 109 | 133 | 190 |
| 40 | 50 | 43 | 55 | 31 | 31 | 54 | 61 | 33 | -1 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 1.13x | 0.77x | 0.66x | 0.66x | 0.48x | 0.49x | 0.52x | 0.49x | 0.67x | 0.59x |
| Interest Coverage (x) | 3.58x | 4.11x | 3.49x | 0.34x | 1.60x | 5.24x | 3.48x | 1.17x | 0.21x | 1.33x |
| 1.37x | 1.23x | 1.23x | 1.16x | 1.09x | 1.23x | 1.42x | 1.24x | 1.10x | 1.08x | |
| GROWTH | ||||||||||
| Revenue Growth % | 33.75% | 2.67% | -7.76% | -18.54% | 24.07% | 36.25% | 17.25% | -17.47% | -0.98% | -13.66% |
| Operating Profit Growth % | 84.48% | 22.54% | 3.18% | -79.04% | 148.80% | 133.25% | -15.30% | -46.77% | -33.13% | 107.53% |
| Net Profit Growth % | 161.07% | 38.93% | -10.71% | -140.38% | 202.76% | 238.94% | -29.72% | -93.54% | -812.51% | 176.52% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -812.48% | 176.52% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 16.97x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 1.03x | 0.79x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 13.76x | 5.60x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-01 - Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-31 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
2026-08-17 - Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest
2026-08-13 - Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-12 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Change in Auditors of the company.
2026-08-12 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Change in Auditors of the company.
2026-08-12 - Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-06 - Mangalam Drugs And Organics Limited has informed the Exchange about General Updates
2026-07-16 - Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest
News
Recent coverage and analyst commentary for MANGALAM
Loading news…
AI Stock Analyst
Mangalam Drugs And Organics Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account